# CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention

Study · id `cardio:ct-nct06283888` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06283888](<https://clinicaltrials.gov/study/NCT06283888>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06283888

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.

## Technical summary

Registry record NCT06283888. Randomized; no masking; primary purpose treatment. Start 2024-04-01 (anticipated); primary completion 2028-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1200 participants (planned count; ClinicalTrials.gov record NCT06283888, source copy `cardio:ctgov-nct06283888-2024-03-20`, retrieved 2026-10-31)
- Planned start: 2024-04-01 (anticipated) (ClinicalTrials.gov record NCT06283888, source copy `cardio:ctgov-nct06283888-2024-03-20`, retrieved 2026-10-31)
- Primary completion: 2028-04-01 (anticipated) (ClinicalTrials.gov record NCT06283888, source copy `cardio:ctgov-nct06283888-2024-03-20`, retrieved 2026-10-31)
- Completion: 2028-12-01 (anticipated) (ClinicalTrials.gov record NCT06283888, source copy `cardio:ctgov-nct06283888-2024-03-20`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06283888, source copy `cardio:ctgov-nct06283888-2024-03-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06283888-2024-03-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
- Condition: ACS - Acute Coronary Syndrome
- Condition: CYP2C19 Polymorphism
- Intervention (Drug): CYP2C19 Genotype Guided DAPT
- Intervention (Drug): Conventional DAPT
- Lead sponsor: Zunyi Medical College
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Zunyi Medical College (`cardio:org-zunyi-medical-college`)

## Provenance

Content hash: 60d5404c0de1439dc6ec47f31aa9e35ffd7ebcc14246ed63c70ea2643f9509b8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
